In this pilot screening study, five herbal medicinal products, marketed for the treatment of respiratory infections [5–8], were explored for their potential to (i) interfere with the binding of the human angiotensin-converting enzyme 2 (ACE2) receptor with the SARS-CoV-2 spike protein. Here, ACE2 is linked to respiratory tract infectious disorder.